Narval
A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal and skin tissues
A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal and skin tissues
Narval is a biotechnology startup founded in 2023, focusing on pioneering a new generation of antibody drugs using synthetic proteins that mimic the activity of antibodies. The company's slogan is "A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal and skin tissues". This innovative approach allows for the delivery of the drugs through mucosal and skin tissues to treat diseases on the eyes, lungs, and skin. Narval operates within the Biotechnology, Health and Wellness, Life Sciences, and Pharmaceutical industries. The startup received non-equity assistance investment from MassChallenge on 26 July 2023.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
26 Jul 2023 |
No recent news or press coverage available for Narval.
We care about your data, and we'd love to use cookies make your experience better.